Tranexamic Acid (TXA) Dosing in Primary Total Knee Arthroplasty
Are You Eligible?The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement.
Research Objectives
Status
Recruitment
Estimated completion
Total participants required
Study location
Study type
Patient group
About this clinical trial
The purpose of the study is to evaluate a product called Tranexamic Acid (TXA) and its best use in patients who are undergoing total knee replacement. The product is currently used to reduce bleeding during and after surgical procedures. This can lessen the chance of you needing a blood transfusion and may decrease pain, swelling and recovery time following the operation. Tranexamic Acid is already routinely used by surgeons for patients having joint replacements but there is currently no accurate information about the best dosing of the drug to achieve optimal patient outcomes. This study will assess whether different treatment durations will lead to better results for patients.
Eligibility
Do you meet the following criteria?
People undergoing primary unilateral Total Knee Arthroplasty.
Additional information
You can find out more about this clinical trial by visiting the ANZCTR website.
Lead investigator
- Dr Sue Clark
Clinical trial coordinator
- Emma Brownrigg
Technical title
A Prospective, Randomised Non-Blinded Pilot Study to Optimise Oral Tranexamic Acid Dosing in Primary Total Knee Arthroplasty (TXA002)
Register your interest
If you would like more information about this clinical trial, please complete the contact form below.